Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (4): 336-342.DOI: 10.3969/j.issn.1673-8640.2024.04.005
Previous Articles Next Articles
YAN Tianqing, YANG Xiaoxiang, GUO Lin, LU Renquan()
Received:
2023-10-25
Revised:
2024-01-11
Online:
2024-04-30
Published:
2024-05-07
CLC Number:
YAN Tianqing, YANG Xiaoxiang, GUO Lin, LU Renquan. Roles of serum cytokine determinations in progression of epithelial ovarian cancer[J]. Laboratory Medicine, 2024, 39(4): 336-342.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.04.005
项目 | IL-1β | IL-2 | IL-4 | IL-5 | IL-6 | IL-8 |
---|---|---|---|---|---|---|
阴性 | 48(71.6) | 44(65.7) | 50(74.6) | 47(70.1) | 10(14.9) | 40(59.7) |
阳性 | 19(28.4) | 23(34.3) | 17(25.4) | 20(29.9) | 57(85.1) | 27(40.3) |
项目 | IL-10 | IL-12 | IL-17 | IFN-α | IFN-γ | TNF-α |
阴性 | 34(50.7) | 65(97.0) | 49(73.1) | 43(64.2) | 52(77.6) | 48(71.6) |
阳性 | 33(49.3) | 2(3.0) | 18(26.9) | 24(35.8) | 15(22.4) | 19(28.4) |
项目 | IL-1β | IL-2 | IL-4 | IL-5 | IL-6 | IL-8 |
---|---|---|---|---|---|---|
阴性 | 48(71.6) | 44(65.7) | 50(74.6) | 47(70.1) | 10(14.9) | 40(59.7) |
阳性 | 19(28.4) | 23(34.3) | 17(25.4) | 20(29.9) | 57(85.1) | 27(40.3) |
项目 | IL-10 | IL-12 | IL-17 | IFN-α | IFN-γ | TNF-α |
阴性 | 34(50.7) | 65(97.0) | 49(73.1) | 43(64.2) | 52(77.6) | 48(71.6) |
阳性 | 33(49.3) | 2(3.0) | 18(26.9) | 24(35.8) | 15(22.4) | 19(28.4) |
项目 | CA125+HE4 | 项目 | CA125+HE4 | ||||
---|---|---|---|---|---|---|---|
双阴性 | 单阳性 | 双阳性 | 双阴性 | 单阳性 | 双阳性 | ||
IL-1β | IL-10 | ||||||
阴性 | 4 | 6 | 38 | 阴性 | 5 | 4 | 25 |
阳性 | 2 | 4 | 13 | 阳性 | 1 | 6 | 26 |
χ2值 | 0.947 | χ2值 | 3.072 | ||||
P值 | 0.623 | P值 | 0.215 | ||||
IL-2 | IL-12 | ||||||
阴性 | 5 | 5 | 34 | 阴性 | 6 | 9 | 50 |
阳性 | 1 | 5 | 17 | 阳性 | 0 | 1 | 1 |
χ2值 | 1.942 | χ2值 | 2.520 | ||||
P值 | 0.379 | P值 | 0.423 | ||||
IL-4 | IL-17 | ||||||
阴性 | 2 | 9 | 39 | 阴性 | 4 | 5 | 40 |
阳性 | 4 | 1 | 12 | 阳性 | 2 | 5 | 11 |
χ2值 | 6.743 | χ2值 | 3.580 | ||||
P值 | 0.034 | P值 | 0.167 | ||||
IL-5 | IFN-α | ||||||
阴性 | 5 | 5 | 37 | 阴性 | 3 | 4 | 36 |
阳性 | 1 | 5 | 14 | 阳性 | 3 | 6 | 15 |
χ2值 | 2.577 | χ2值 | 3.979 | ||||
P值 | 0.276 | P值 | 0.137 | ||||
IL-6 | IFN-γ | ||||||
阴性 | 0 | 2 | 8 | 阴性 | 2 | 6 | 44 |
阳性 | 6 | 8 | 43 | 阳性 | 4 | 4 | 7 |
χ2值 | 0.946 | χ2值 | 10.758 | ||||
P值 | 0.597 | P值 | 0.005 | ||||
IL-8 | TNF-α | ||||||
阴性 | 4 | 5 | 31 | 阴性 | 1 | 8 | 39 |
阳性 | 2 | 5 | 20 | 阳性 | 5 | 2 | 12 |
χ2值 | 0.537 | χ2值 | 9.855 | ||||
P值 | 0.765 | P值 | 0.007 |
项目 | CA125+HE4 | 项目 | CA125+HE4 | ||||
---|---|---|---|---|---|---|---|
双阴性 | 单阳性 | 双阳性 | 双阴性 | 单阳性 | 双阳性 | ||
IL-1β | IL-10 | ||||||
阴性 | 4 | 6 | 38 | 阴性 | 5 | 4 | 25 |
阳性 | 2 | 4 | 13 | 阳性 | 1 | 6 | 26 |
χ2值 | 0.947 | χ2值 | 3.072 | ||||
P值 | 0.623 | P值 | 0.215 | ||||
IL-2 | IL-12 | ||||||
阴性 | 5 | 5 | 34 | 阴性 | 6 | 9 | 50 |
阳性 | 1 | 5 | 17 | 阳性 | 0 | 1 | 1 |
χ2值 | 1.942 | χ2值 | 2.520 | ||||
P值 | 0.379 | P值 | 0.423 | ||||
IL-4 | IL-17 | ||||||
阴性 | 2 | 9 | 39 | 阴性 | 4 | 5 | 40 |
阳性 | 4 | 1 | 12 | 阳性 | 2 | 5 | 11 |
χ2值 | 6.743 | χ2值 | 3.580 | ||||
P值 | 0.034 | P值 | 0.167 | ||||
IL-5 | IFN-α | ||||||
阴性 | 5 | 5 | 37 | 阴性 | 3 | 4 | 36 |
阳性 | 1 | 5 | 14 | 阳性 | 3 | 6 | 15 |
χ2值 | 2.577 | χ2值 | 3.979 | ||||
P值 | 0.276 | P值 | 0.137 | ||||
IL-6 | IFN-γ | ||||||
阴性 | 0 | 2 | 8 | 阴性 | 2 | 6 | 44 |
阳性 | 6 | 8 | 43 | 阳性 | 4 | 4 | 7 |
χ2值 | 0.946 | χ2值 | 10.758 | ||||
P值 | 0.597 | P值 | 0.005 | ||||
IL-8 | TNF-α | ||||||
阴性 | 4 | 5 | 31 | 阴性 | 1 | 8 | 39 |
阳性 | 2 | 5 | 20 | 阳性 | 5 | 2 | 12 |
χ2值 | 0.537 | χ2值 | 9.855 | ||||
P值 | 0.765 | P值 | 0.007 |
项目 | Th1型细胞因子① | Th2型细胞因子② | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
三阴③/例 | 单阳④/例 | 双阳⑤/例 | 三阳⑥/例 | 总阳性率/% | 三阴③/例 | 单阳④/例 | 双阳⑤/例 | 三阳⑥/例 | 总阳性率/% | ||
FIGO分期 | |||||||||||
早期 | 0 | 1 | 0 | 1 | 100.0 | 0 | 1 | 0 | 1 | 100.0 | |
进展期 | 27 | 24 | 13 | 1 | 58.5 | 4 | 23 | 34 | 4 | 93.8 | |
χ2值 | 7.122 | 5.444 | |||||||||
P值 | 0.001 | 0.099 | |||||||||
组织学类型 | |||||||||||
非浆液性 | 3 | 1 | 0 | 0 | 25.0 | 0 | 2 | 2 | 0 | 100.0 | |
浆液性 | 24 | 24 | 13 | 2 | 61.9 | 4 | 22 | 32 | 5 | 93.7 | |
χ2值 | 2.257 | 0.830 | |||||||||
P值 | 0.576 | 1.000 | |||||||||
病理分级 | |||||||||||
低级别 | 0 | 1 | 0 | 0 | 100.0 | 0 | 1 | 0 | 0 | 100.0 | |
高级别 | 27 | 24 | 13 | 2 | 59.1 | 4 | 23 | 34 | 5 | 93.9 | |
χ2值 | 3.549 | 3.703 | |||||||||
P值 | 0.597 | 0.493 | |||||||||
淋巴结转移 | |||||||||||
否 | 10 | 8 | 3 | 1 | 54.5 | 3 | 10 | 7 | 2 | 86.4 | |
是 | 17 | 17 | 10 | 1 | 62.2 | 1 | 14 | 27 | 3 | 97.8 | |
χ2值 | 1.355 | 6.502 | |||||||||
P值 | 0.769 | 0.090 | |||||||||
腹水 | |||||||||||
否 | 7 | 6 | 7 | 1 | 66.7 | 0 | 10 | 10 | 1 | 100.0 | |
是 | 20 | 19 | 6 | 1 | 56.5 | 4 | 14 | 24 | 4 | 91.3 | |
χ2值 | 4.491 | 3.373 | |||||||||
P值 | 0.203 | 0.338 | |||||||||
影像学提示转移 | |||||||||||
否 | 16 | 19 | 6 | 0 | 61.0 | 3 | 19 | 16 | 3 | 92.7 | |
是 | 16 | 6 | 7 | 2 | 48.4 | 1 | 5 | 18 | 2 | 96.2 | |
χ2值 | 6.282 | 6.449 | |||||||||
P值 | 0.078 | 0.092 |
项目 | Th1型细胞因子① | Th2型细胞因子② | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
三阴③/例 | 单阳④/例 | 双阳⑤/例 | 三阳⑥/例 | 总阳性率/% | 三阴③/例 | 单阳④/例 | 双阳⑤/例 | 三阳⑥/例 | 总阳性率/% | ||
FIGO分期 | |||||||||||
早期 | 0 | 1 | 0 | 1 | 100.0 | 0 | 1 | 0 | 1 | 100.0 | |
进展期 | 27 | 24 | 13 | 1 | 58.5 | 4 | 23 | 34 | 4 | 93.8 | |
χ2值 | 7.122 | 5.444 | |||||||||
P值 | 0.001 | 0.099 | |||||||||
组织学类型 | |||||||||||
非浆液性 | 3 | 1 | 0 | 0 | 25.0 | 0 | 2 | 2 | 0 | 100.0 | |
浆液性 | 24 | 24 | 13 | 2 | 61.9 | 4 | 22 | 32 | 5 | 93.7 | |
χ2值 | 2.257 | 0.830 | |||||||||
P值 | 0.576 | 1.000 | |||||||||
病理分级 | |||||||||||
低级别 | 0 | 1 | 0 | 0 | 100.0 | 0 | 1 | 0 | 0 | 100.0 | |
高级别 | 27 | 24 | 13 | 2 | 59.1 | 4 | 23 | 34 | 5 | 93.9 | |
χ2值 | 3.549 | 3.703 | |||||||||
P值 | 0.597 | 0.493 | |||||||||
淋巴结转移 | |||||||||||
否 | 10 | 8 | 3 | 1 | 54.5 | 3 | 10 | 7 | 2 | 86.4 | |
是 | 17 | 17 | 10 | 1 | 62.2 | 1 | 14 | 27 | 3 | 97.8 | |
χ2值 | 1.355 | 6.502 | |||||||||
P值 | 0.769 | 0.090 | |||||||||
腹水 | |||||||||||
否 | 7 | 6 | 7 | 1 | 66.7 | 0 | 10 | 10 | 1 | 100.0 | |
是 | 20 | 19 | 6 | 1 | 56.5 | 4 | 14 | 24 | 4 | 91.3 | |
χ2值 | 4.491 | 3.373 | |||||||||
P值 | 0.203 | 0.338 | |||||||||
影像学提示转移 | |||||||||||
否 | 16 | 19 | 6 | 0 | 61.0 | 3 | 19 | 16 | 3 | 92.7 | |
是 | 16 | 6 | 7 | 2 | 48.4 | 1 | 5 | 18 | 2 | 96.2 | |
χ2值 | 6.282 | 6.449 | |||||||||
P值 | 0.078 | 0.092 |
[1] |
KURMAN R J, SHIH I E M. The origin and pathogenesis of epithelial ovarian cancer:a proposed unifying theory[J]. Am J Surg Pathol, 2010, 34(3):433-443.
DOI URL |
[2] | NASH Z, MENON U. Ovarian cancer screening:current status and future directions[J]. Best Pract Res Clin Obstet Gynaecol, 2020,65:32-45. |
[3] |
SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics,2023[J]. CA Cancer J Clin, 2023, 73(1):17-48.
DOI URL |
[4] | XIA C, DONG X, LI H, et al. Cancer statistics in China and United States,2022:profiles,trends,and determinants[J]. Chin Med J(Engl), 2022, 135(5):584-590. |
[5] |
BURKHOLDER B, HUANG R Y, BURGESS R, et al. Tumor-induced perturbations of cytokines and immune cell networks[J]. Biochim Biophys Acta, 2014, 1845(2):182-201.
DOI PMID |
[6] | 韦安猛, 张伟华, 张春玲, 等. 肺癌患者化疗前后Th1/Th2细胞因子免疫反应状态变化及对预后的影响[J]. 实用癌症杂志, 2022, 37(5):746-751. |
[7] |
LEONARD W J, LIN J X. Strategies to therapeutically modulate cytokine action[J]. Nat Rev Drug Discov, 2023, 22(10):827-854.
DOI PMID |
[8] |
黄群欢, 洪岭, 陶春林, 等. 不同分期宫颈癌患者外周血Treg和相关细胞因子差异分析[J]. 检验医学, 2017, 32(9):769-772.
DOI |
[9] | HERRERA F G, IRVING M, KANDALAFT L E, et al. Rational combinations of immunotherapy with radiotherapy in ovarian cancer[J]. Lancet Oncol, 2019, 20(8):e417-e433. |
[10] |
薛艳, 王佳佳, 王馥香, 等. CLIC4、SNHG3表达与Ⅰ-Ⅱ期卵巢癌患者预后的关系[J]. 检验医学, 2021, 36(10):1026-1032.
DOI |
[11] |
王振华, 应晓. HE4和CA125联合检测在妇科盆腔肿块中的应用[J]. 检验医学, 2015, 30(5):545-546.
DOI |
[12] | 孙昕, 鲍扬漪, 鲍键. 乳腺癌患者血清肿瘤标志物及细胞因子的临床意义[J]. 中国医药科学, 2011, 1(13):17-20. |
[13] | 马麟娟, 李小清. 卵巢癌患者手术前后外周血Th1/Th2细胞因子表达[J]. 全科医学临床与教育, 2010, 8(3):254-256. |
[14] | LACALLE R A, BLANCO R, CARMONA-RODRÍGUEZ L, et al. Chemokine receptor signaling and the hallmarks of cancer[J]. Int Rev Cell Mol Biol, 2017,331:181-244. |
[15] |
聂甜, 冉子涵, 金磊. 白细胞介素基因多态性与胃癌的相关性研究进展[J]. 检验医学, 2022, 37(9):882-886.
DOI |
[16] |
HEINRICH P C, BEHRMANN I, HAAN S, et al. Principles of interleukin(IL)-6-type cytokine signalling and its regulation[J]. Biochem J, 2003, 374(Pt 1):1-20.
DOI URL |
[17] |
DOBRZYCKA B, MACKOWIAK-MATEJCZYK B, TERLIKOWSKA K M, et al. Serum levels of IL-6,IL-8 and CRP as prognostic factors in epithelial ovarian cancer[J]. Eur Cytokine Netw, 2013, 24(3):106-113.
DOI URL |
[18] |
CLENDENEN T V, LUNDIN E, ZELENIUCH-JACQUOTTE A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer[J]. Cancer Epidemiol Biomarkers Prev, 2011, 20(5):799-810.
DOI URL |
[19] |
MACCIÒA, MADEDDU C, MASSA D, et al. Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients[J]. J Cell Mol Med, 2009, 13(9B):3951-3959.
DOI PMID |
[20] |
DOBRZYCKA B, TERLIKOWSKI S J, KOWALCZUK O, et al. Circulating levels of TNF-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer[J]. Eur Cytokine Netw, 2009, 20(3):131-134.
DOI PMID |
[21] |
GALIZIA G, LIETO E, DE VITA F, et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery:relationship with radicality and outcome[J]. J Interferon Cytokine Res, 2002, 22(4):473-482.
DOI URL |
[22] |
BLOCK M S, DIETZ A B, GUSTAFSON M P, et al. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients[J]. Nat Commun, 2020, 11(1):5173.
DOI PMID |
[1] | ZHANG Han, GUO Lin, LU Renquan, CHEN Fuxiang. Clinical value and prospect of peripheral blood immune indexes in cancer patients [J]. Laboratory Medicine, 2024, 39(4): 311-316. |
[2] | TAN Meiyu, SHU Jie, XUAN Binbin, ZHOU Lida, LI Hong, HOU Shangwei, SHENG Huiming. Effects of SARS-CoV-2 vaccination on antibody production and immune function [J]. Laboratory Medicine, 2022, 37(8): 729-734. |
[3] | HE Yaya, CHEN Shanshan, LI Yongsheng, LIU Juan. Expressions of sLAIR-1 and LAIR-1 mRNA in AS patients and their relationship with disease activity [J]. Laboratory Medicine, 2022, 37(10): 915-920. |
[4] | GAO Weixia, QIN Xiaowan, LIU Yang, ZHANG Jing, DING Xianchun. Clinical significance of inflammatory cell types and inflammatory cytokines in sputum induced by bronchial asthma in children [J]. Laboratory Medicine, 2021, 36(1): 69-74. |
[5] | WEI Jianhao, GUO Qian, LI Haicong, HAO Menglu, XU Sheng, QI Weiqiang, LING Yun, HAN Weijing, LIU Yili, ZHU Zhaoqin. Analysis of laboratory determination data of 328 corona virus disease 2019 patients in Shanghai [J]. Laboratory Medicine, 2020, 35(8): 778-783. |
[6] | PENG Xinguo, SUN Changhua, AN Jiajia, CUI Yanfang, DONG Yan, WANG Jian, GAO Meilan. Immune reconstitution after allogeneic hematopoietic stem cell transplantation and its correlation with fungal infection [J]. Laboratory Medicine, 2020, 35(5): 447-450. |
[7] | JI Tianhao, CHEN Junyi, MENG Yadong. Therapeutic effect and mechanism of compound Qingdai capsule combined with MTX in the treatment of psoriasis [J]. Laboratory Medicine, 2020, 35(2): 120-124. |
[8] | KE Xing, ZHANG Liang, SHEN Lisong. Preliminary study on the mechanism of CD4+CD25highCD127low regulatory T cells promoting the metastasis of epithelial ovarian cancer [J]. Laboratory Medicine, 2019, 34(2): 110-115. |
[9] | LI Zebing, LI Dong, YANG Xuesong, SUN Zujun, LIN Ping, WANG Feng, LIN Feiran, XU Xiao, XIE Hongtao. Expression levels and their roles of serum IL-1β,IL-6,TNF-α,IL-17 and IL-23 of schizophrenia patients [J]. Laboratory Medicine, 2018, 33(8): 697-701. |
[10] | DING Bingyu, LIN Ping, LI Qingtian. Th1/Th2 cytokines secreted by phytohaemagglutinin-stimulated peripheral blood mononuclear cells for the diagnosis of Alzheimer's disease [J]. Laboratory Medicine, 2018, 33(4): 290-294. |
[11] | HE LIU Jichuan. Correlation of the kinds of gut bacteria with serum inflammatory cytokines in patients with chronic [J]. Laboratory Medicine, 2018, 33(10): 907-912. |
[12] | YANG Huikuan, YUAN Zhaohu, CHEN Xiaojie, WEI Yaming, CHEN Dandan. Inhibition of DC-CIK VISTA signal for improving the anti-tumor effect of malignant tumor cells [J]. Laboratory Medicine, 2018, 33(10): 933-937. |
[13] | HUANG Qunhuan, HONG Ling, TAO Chunlin, HUANG Xuhong. Regulator T cells and cytokines in peripheral blood of cervical cancer patients with different stages [J]. Laboratory Medicine, 2017, 32(9): 769-772. |
[14] | GUO Lichao, LI Jiao, WEI Xiaolong. Cerebral spinal fluid determination in the diagnosis of central nervous system infections [J]. Laboratory Medicine, 2016, 31(4): 334-337. |
[15] | XU Cheng, XU Yuanhong. The research progress of early warning biomarker for sepsis [J]. Laboratory Medicine, 2015, 30(5): 533-536. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||